Emory University Nell Hodgson Woodruff School of Nursing, 1520 Clifton Rd, Atlanta, GA, 30322, USA.
Emory University Department of Computer Science, Atlanta, GA, USA.
Comput Biol Med. 2021 Jul;134:104461. doi: 10.1016/j.compbiomed.2021.104461. Epub 2021 May 2.
This study uses machine learning techniques to identify sociodemographic and clinical predictors of progression through the hepatitis C (HCV) cascade of care for patients in the 1945-1965 birth cohort in the Southern United States.
We compared sociodemographic and clinical variables between groups of patients for three care outcomes: linkage to care, initiation of antiviral treatment, and virologic cure. A decision tree model and random forest model were built for each outcome.
Patients were primarily male, African American/Black or Caucasian/White, non-Hispanic or Latino, and insured. The average age at first HCV screening was 60 years old, and common medical diagnoses included chronic kidney disease, fibrosis and/or cirrhosis, transplanted liver, diabetes mellitus, and liver cell carcinoma. Variables used in predicting linkage to care included age at first HCV screening, insurance at first HCV screening, race, fibrosis and/or cirrhosis, other liver disease, ascites, and transplanted liver. Variables used in predicting initiation of antiviral treatment included insurance at first HCV screening, gender, other liver cancer, steatosis, and liver cell carcinoma. Variables used in predicting virologic cure included insurance at first HCV screening, transplanted liver, and ethnicity.
These patients have a high hepatic health burden, likely reflecting complications of untreated HCV and highlighting the urgency to cure HCV in this birth cohort. We found differences in HCV care outcomes based on sociodemographic and clinical variables. More work is needed to understand the mechanisms of these differences in care outcomes and to improve HCV care.
本研究使用机器学习技术来识别美国南部 1945-1965 年出生队列患者通过丙型肝炎(HCV)治疗途径的社会人口学和临床预测因素。
我们比较了三组患者的社会人口学和临床变量,以确定三个治疗结果:与治疗的关联、抗病毒治疗的开始和病毒学治愈。为每个结果构建了决策树模型和随机森林模型。
患者主要为男性,非裔/黑人或白种人,非西班牙裔或拉丁裔,且有保险。首次 HCV 筛查的平均年龄为 60 岁,常见的医疗诊断包括慢性肾脏病、纤维化和/或肝硬化、移植肝脏、糖尿病和肝细胞癌。用于预测与治疗关联的变量包括首次 HCV 筛查的年龄、首次 HCV 筛查时的保险情况、种族、纤维化和/或肝硬化、其他肝病、腹水和移植肝脏。用于预测开始抗病毒治疗的变量包括首次 HCV 筛查时的保险情况、性别、其他肝癌、脂肪变性和肝细胞癌。用于预测病毒学治愈的变量包括首次 HCV 筛查时的保险情况、移植肝脏和种族。
这些患者的肝脏健康负担较高,可能反映了未治疗 HCV 的并发症,突出了在这个出生队列中治愈 HCV 的紧迫性。我们发现,社会人口学和临床变量与 HCV 治疗结果存在差异。需要更多的工作来了解这些治疗结果差异的机制,并改善 HCV 的治疗。